Scholar Rock Holding Corporation (SRRK)
| Market Cap | 5.14B +38.2% |
| Revenue (ttm) | n/a |
| Net Income | -408.59M |
| EPS | -3.36 |
| Shares Out | 121.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,258,329 |
| Open | 42.18 |
| Previous Close | 42.20 |
| Day's Range | 41.81 - 42.82 |
| 52-Week Range | 27.07 - 61.76 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 70.44 (+66.96%) |
| Est. Earnings | Nov 13, 2026 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFβ) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or laten... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SRRK stock is "Strong Buy." The 12-month stock price target is $70.44, which is an increase of 66.96% from the latest price.
News
Scholar Rock resubmits MAA for apitegromab to the EMA
Scholar Rock (SRRK) announced it has resubmitted the Marketing Authorisation Application, MAA, for apitegromab for the treatment of children and adults with spinal muscular atrophy, SMA, to the Europe...
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock added to Best Ideas List at Wedbush
Wedbush is adding Outperform-rated Scholar Rock (SRRK) to the firm’s Best Ideas List. Wedbush believes the company is uniquely positioned to deliver a durable, derisked commercial ramp in the neuromus...
Scholar Rock price target raised to $77 from $76 at Truist
Truist raised the firm’s price target on Scholar Rock (SRRK) to $77 from $76 and keeps a Buy rating on the shares. The firm notes that its key opinion leader…
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common sto...
Scholar Rock price target raised to $70 from $63 at JPMorgan
JPMorgan raised the firm’s price target on Scholar Rock (SRRK) to $70 from $63 and keeps an Overweight rating on the shares following the FDA approval of Isembyld. The firm…
Scholar Rock says FDA requested pregnancy safety study for Isembyld
Scholar Rock (SRRK) disclosed earlier today on a live audio webcast yesterday announcing the Food and Drug Administration has approved Isembyld, the company’s management stated in error that the FDA…
Scholar Rock Stock (SRRK) Slides Over 7% on an FDA Safety Update
Scholar Rock stock dropped over 7% on Tuesday after an FDA update related to safety terms for approval of ISEMBYLD.
Scholar Rock price target raised to $72 from $65 at Evercore ISI
Evercore ISI raised the firm’s price target on Scholar Rock (SRRK) to $72 from $65 and keeps an Outperform rating on the shares. Approval of Isembyld “marks a significant advancement”…
Scholar Rock price target raised to $70 from $64 at Wedbush
Wedbush raised the firm’s price target on Scholar Rock (SRRK) to $70 from $64 and keeps an Outperform rating on the shares post the company’s update. The firm is revising…
Scholar Rock price target raised to $75 from $60 at Piper Sandler
Piper Sandler analyst Allison Bratzel raised the firm’s price target on Scholar Rock (SRRK) to $75 from $60 and keeps an Overweight rating on the shares. The firm attributes the…
Scholar Rock price target raised to $70 from $65 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Scholar Rock (SRRK) to $70 from $65 and keeps a Buy rating on the shares following FDA approval of Isembyld. The label…
Barclays downgrades Scholar Rock on valuation after FDA approval
Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval of Isembyld represents a major milestone…
Scholar Rock downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a $58 price target
Scholar Rock price target raised to $65 from $57 at Jefferies
Jefferies analyst Amy Li raised the firm’s price target on Scholar Rock (SRRK) to $65 from $57 and keeps a Buy rating on the shares after the FDA approved apitegromab…
Scholar Rock price target raised to $72 from $65 at Raymond James
Raymond James raised the firm’s price target on Scholar Rock (SRRK) to $72 from $65 and keeps a Strong Buy rating on the shares. Scholar Rock’s FDA approval of ISEMBYLD…
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Scholar Rock on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients with...
Scholar Rock Holding Transcript: FDA announcement
ISEMBYLD received FDA approval as the first muscle-targeted therapy for SMA, offering significant motor function improvements and a strong safety profile. The U.S. launch is underway, with broad patient eligibility, robust support programs, and global expansion plans.
Scholar Rock Holding Press release: FDA announcement
Scholar Rock Holding issued a press release on September 14, 2026, disclosing material business information to investors.
Scholar Rock price target raised to $84 from $76 at BMO Capital
BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of isembyld, coupled with…
Scholar Rock price target raised to $76 from $55 at Truist
Truist raised the firm’s price target on Scholar Rock (SRRK) to $76 from $55 and keeps a Buy rating on the shares. The company’s lead asset apitegromab has been approved…
Scholar Rock price target raised to $74 from $60 at Citi
Citi raised the firm’s price target on Scholar Rock (SRRK) to $74 from $60 and keeps a Buy rating on the shares. The approval of Isembyld removes the main overhang…
Scholar Rock Holdings trading resumes
18:45 EDT Scholar Rock (SRRK) Holdings trading resumes
Scholar Rock announces FDA approval of isembyld
Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of age and older who are currently…
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...